BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant — BRESELIBET

Hodgkin Lymphoma, Adult Clinical Trial

Official title:
A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy With Brentuximab Vedotin-ESHAP vs ESHAP in Patients With Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by Brentuximab Vedotin Consolidation (Instead of Autologous Hematopoietic Stem Cell Transplantation) in Those Who Attained a Metabolic Complete Remission After Salvage Therapy

Status Recruiting

Clinical Trial Summary

A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy

Clinical Trial Description

A phase IIb open label multi-center trial in patients with refractory / relapsed cHL. Patients are randomized (1:1) to receive: • ESHAP- BV (Etoposide [40 mg/m2/ day IV, D1-4], Solumedrol [250 mg/day IV, D1-4], high dose Ara-C [2 g/m2 IV, D5] and cisplatinum [25 mg/m2/day IV, D1-4] + BV [1.8 mg/kg IV, D1], every 21 days (3 cycles, q21 days). Or • ESHAP (Etoposide [40 mg/m2/ day IV, D1-4], Solumedrol [250 mg/day IV, D1-4], high dose Ara-C [2 g/m2 IV, D5] and cisplatinum [25 mg/m2/day IV, D1-4] (3 cycles, q21 days) Stem cell collection will be performed in all patients according to institutional guidelines, but preferably after the first / second cycle of ESHAP-BV or ESHAP. Patients attaining a mCR (Deauville 1, 2) after receiving 3 cycles of ESHAP-BV, will receive up to 13 cycles of BV consolidation (administered every 3 weeks, over 39 weeks). Patients who were randomized to ESHAP and attained a mCR after receiving 3 cycles will receive up to 16 cycles of BV (same dosage and time intervals). Patients who attained less than mCR following ESHAP-BV/ESHAP they will be taken out of the trial and will be treated according to their physician's clinical decision. However, they will be followed in order to evaluate their clinical outcome in terms of ORR, CR rate, TTNT2 and OS, that will be analyzed the study separately. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04378647
Study type	Interventional
Source	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Contact	lucia palacios, MSc
Phone	+18599134526
Email	ensayosclinicos01@geltamo.com
Status	Recruiting
Phase	Phase 2
Start date	June 1, 2020
Completion date	August 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04653649` - CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.	Phase 1/Phase 2
Recruiting	`NCT04636255` - Physical Capacity in Hodgkin Lymphoma Survivors	N/A
Not yet recruiting	`NCT06421987` - Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors
Recruiting	`NCT05597761` - Immunogenicity of COVID-19 Vaccination in Autologous HSCT or CAR-T Cells Recipients
Active, not recruiting	`NCT03535948` - Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy
Completed	`NCT03155425` - PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma	Phase 2
Recruiting	`NCT03260101` - Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
Recruiting	`NCT04776265` - RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT
Recruiting	`NCT04758650` - Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis	Phase 2
Recruiting	`NCT05137886` - PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma	Phase 2
Recruiting	`NCT05798897` - Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma	Phase 1
Completed	`NCT04292626` - Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose	Phase 1
Active, not recruiting	`NCT04268706` - Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)	Phase 2
Recruiting	`NCT04638790` - First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)	Phase 3
Completed	`NCT01578967` - Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma	N/A
No longer available	`NCT03914885` - Compassionate Use Re-Infusion of ATLCAR.CD30

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.